In the present study, we found PRAME expression in undifferentiated pleomorphic sarcoma (UPS), malignant peripheral nerve sheath tumour (MPNST), synovial sarcoma, leiomyosarcoma (LMS), angiosarcoma, dedifferentiated liposarcoma (DDLPS), uterine carcinosarcoma, and rhabdomyosarcoma, making PRAME a potential target for immunotherapy in these histological subtypes. This evidence concerns the gene PRAME and rhabdomyosarcoma.